B. Kristine Johnson and Kristina Wright Join Paragon 28 Board

Paragon 28 Inc. has welcomed two new members to its Board of Directors—B. Kristine Johnson and Kristina Wright.

Johnson has been president and general partner of Affinity Capital Management, a venture capital firm, since 2000. Before working at Affinity Capital Management, she held various executive leadership positions at Medtronic from 1982 to 1999. Johnson is currently a board member of AtriCure Inc., ViewRay, and ClearPoint Neuro Inc. Previously, she served as a board member for Piper Sandler and Spectranetics Corporation.

Johnson earned a bachelor of arts degree from St. Olaf College.

“I am pleased to be joining Paragon 28, and I look forward to working with the company’s board and management team to drive its future growth and success, while advancing its innovative technologies to improve outcomes for more foot and ankle patients,” said  Johnson.

Wright has served as vice president and chief financial officer for the Neuromodulation Operating Unit of Medtronic since July 2020. In August 2021, she was named interim general manager for the Brain Modulation business within Neuromodulation. She previously held various leadership positions at Medtronic in both finance and corporate development since August 2010. Before her tenure at Medtronic, Wright worked at PricewaterhouseCoopers LLP in the Audit and Assurance and Transaction Services practices from 1999 to 2010.

Wright earned a bacheloro of science degree in accounting from the University of Minnesota, and an M.B.A from the Fuqua School of Business at Duke University.
 
“I’m thrilled to be able to support Paragon 28 to drive its growth agenda,” said Wright. “The company is well positioned in the large and fast-growing foot and ankle markets and has a solid foundation to deliver on its objectives.”

“I am pleased to welcome Kris Johnson to our board of directors, as she brings a breadth of med-tech industry leadership and commercial strategy expertise. Kris’ expertise in growing medical device businesses will be essential as we expand our commercial infrastructure to be the market leader in the foot and ankle industry,” Paragon 28 Founder and CEO Albert DaCosta said. “We are also excited to welcome Krissy Wright to our board of directors, as she brings a wide range of corporate development and finance expertise in the medical device industry. Krissy’s finance expertise will be critical as we scale our business in the coming years.”
  
Based in Englewood, Colo., Paragon 28, is focused on the foot and ankle orthopedic market. Paragon 28 has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.